Having demonstrated the potential for dual BH3-mimetic targeting of BCL-2 and MCL1 to rapidly induce remissions and extend the survival of mice xenografted with AML, we next examined the tolerance of normal hematopoietic cells to combined S55746/S63845 therapy. Here, BCL2 is linked to acute myeloid leukemia.